(132 days)
Bicanalicular intubation is indicated in treatments of epiphora in adults (not to be used in infants), particularly in cases of:
- Meatic pathologies (meatic atresia)
- Canalicular pathologies (canalicular stricture)
Self-Retaining Bicanaliculus Intubation Set
This document is a 510(k) clearance letter from the FDA for a medical device (Self-Retaining Bicanaliculus Intubation Set). It confirms "substantial equivalence" to a legally marketed predicate device, allowing it to be marketed.
However, the provided text does not contain any information regarding acceptance criteria, device performance studies, sample sizes, expert ground truth establishment, adjudication methods, MRMC studies, or standalone algorithm performance.
The document is purely a regulatory letter stating that the device has been cleared for market based on substantial equivalence. It does not include the technical details of any performance testing or clinical studies that might have been submitted to support that equivalence.
Therefore, I cannot fulfill your request for the specific information about acceptance criteria and study details based on the provided text.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image contains the text 'Public Health Service'. The text is in a simple, sans-serif font and is horizontally aligned. The words are stacked on top of each other.
Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a human figure embracing another, possibly representing care and support.
DEC 16 2008
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FCI Ophthalmics, Inc. c/o Hillard W. Welch 344 Annabelle Point Rd. Centerville, MA 02632
Re: K041869
Trade/Device Name: Self Retaining Bicanaliculus Intubation Set Regulatory Class: Unclassified Product Code: OKS Dated: October 8, 2004 Received: October 15, 2004
Dear Mr. Welch:
This letter corrects our substantially equivalent letter of November 18, 2004.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance. please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mahina B. Egleston, MD
Malvina B. Eydelman, M.I Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Page 3 – Mr. Hillard Welch
Indications for Use
510(k) Number (if known): K041869
Device Name: Self-Retaining Bicanaliculus Intubation Set
Indications For Use:
Bicanalicular intubation is indicated in treatments of epiphora in adults (not to be used in infants), particularly in cases of:
- Meatic pathologies (meatic atresia) ー
Canalicular pathologies (canalicular stricture) -
Prescription Use Counter Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Ben Riemenschneider
Page 1 of
510(k) Number K041869
N/A